CARLHealthcare · Health Information ServicesThe 5 Wall Street analysts covering Carlsmed, Inc. hold a median 12-month price target of $18 — +39.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Carlsmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (84): Analysts have, on balance, been raising their forecasts.
Volatility (11): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Carlsmed, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CARL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +39.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 July 2026 | Needham | Initiates | Buy | $17 |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 15 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 15 Dec 2025 | BTIG | Reiterates | Buy | — |
| 7 Nov 2025 | BTIG | Maintains | Buy | — |
| 7 Nov 2025 | Truist Securities | Reiterates | Buy | — |
| 18 Aug 2025 | Goldman Sachs | Initiates | Buy | — |
| 18 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 18 Aug 2025 | Truist Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 20% of US stocks
Cheaper than 27% of US stocks
Cheaper than 82% of US stocks
Higher than 89% of US stocks
Higher than 80% of US stocks
Higher than 89% of US stocks
Higher than 17% of US stocks
Higher than 9% of US stocks
Higher than 21% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CARL appears on the weeks it earns a place.
Carlsmed announced that the CMS Fiscal Year 2027 Inpatient Final Rule establishes three new MS-DRGs with favorable reimbursement for its aprevo® Lumbar spine fusion procedures.
Why it matters — This reimbursement decision could improve market access and adoption of Carlsmed's aprevo Lumbar system in hospital settings.
A Zacks Investment Research article reports that Carlsmed, Inc. (CARL) lacks the right combination of key ingredients for a likely earnings beat in its upcoming report, suggesting the company may report negative earnings.
Why it matters — CARL watchers would care because the article signals that the upcoming earnings report could fall short of expectations.
Carlsmed, Inc. announced that management will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference.
Why it matters — A CARL watcher would care because investor conference participation can increase the company's visibility among institutional investors and analysts.
The 5 Wall Street analysts covering Carlsmed, Inc. have a median 12-month price target of $18, with estimates ranging from $17 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Carlsmed, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Carlsmed, Inc. 26 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Carlsmed, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +39.2% from the last close, and Ticker Nerd's factor model ranks Carlsmed, Inc. 26 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Carlsmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CARL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $23 over the next 12 months.
Carlsmed, Inc. returned -4.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Carlsmed, Inc. is a commercial-stage medical technology company founded in 2018 and headquartered in Carlsbad, California.
The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures". Carlsmed announced that the CMS Fiscal Year 2027 Inpatient Final Rule establishes three new MS-DRGs with favorable reimbursement for its aprevo® Lumbar spine fusion procedures.
Carlsmed, Inc. is a commercial-stage medical technology company founded in 2018 and headquartered in Carlsbad, California. It specializes in AI-enabled personalized spine surgery solutions, aiming to enhance patient outcomes and reduce healthcare costs in spine fusion procedures. The company's core offering, the aprevo Technology Platform, integrates AI-powered software with custom-designed interbody implants tailored to each patient's unique vertebral bone topography and pathology, complemented by single-use surgical instruments. This comprehensive approach supports surgeons in traditional techniques by providing precise, patient-specific tools that set a new standard in spinal care. Operating within the health care equipment industry, Carlsmed, Inc. employs around 89 professionals and focuses on innovation at the intersection of artificial intelligence and orthopedic surgery. With a market capitalization reflecting its growth trajectory post its 2025 Nasdaq listing, the company plays a pivotal role in advancing precision medicine for complex spinal conditions, potentially transforming surgical efficiency and recovery times across global healthcare systems.
CEO Mr. Michael John Cordonnier · 127 employees · United States · https://carlsmed.com